Ukip unveils new data on anti-inflammatory drug Cimzia (certolizumab pegol)

recently, BelgianPharmaceutical(http://giant UCB released new data on the anti-inflammatory drug Cimzia (certolizumab pegol), supporting the long-term safety of Cimzia's treatment of adult patients with moderate to severe plaque psoriasisThis new safetyanalysis(http://aggregates 96 weeks of safety data from three ongoing clinical studies (CIMPASI-1, CIMPASI-2, CIMPACT)The three studies evaluated the efficacy and safety of Cimzia's treatment of adult patients with moderate to severe plaque psoriasis, and enrolled in a total of about 1,000 patients, including those who had previously received and were not treated with biologics, who had moderate to severe plaque-type psoriasis for at least 6 months (PASI,12, 10% BSA, 5 pga 3)instudies, patients were randomly given a 400 mg dose of Cimzia every 2 weeks, a dose of Cimzia at 200 mg (400 mg at an initial load dose of 0, 2, 4 weeks), a placebo, or 2 50 mg doses per week in enasip (CIMPACT only)A total of 995 patients received at least one dose of Cimzia treatment over a 96-week period, including initial, maintenance, and open labelingIf the adverse event occurs within 10 weeks of the last Cimzia administration, it is includedThe incidence of adverse events is calculated as the incidence of new cases per 100 patients per 100 yearsThe summary analysis showed that no new safety signals were observed, that Cimzia's safety profile was consistent with other anti-tumor necrosis factors (anti-TNF) for psoriasis treatment, and that the overall incidence of adverse events was lowThe observed incidence of adverse events after 16 weeks, Cimzia and placebo was comparable, and the risk of adverse events up to 96 weeks did not appear to increase with the longer duration of Cimzia exposureAt the end of March, Cimzia was approved by the U.S FDA (http:// a new indication for the treatment of adult patients with active non-radiative non-radian spinal arthritis (nr-axSpA) with inflammatory signs this approval, making Cimzia the first and only drug (http:// approved by the FDA for nr-axSpA